CD274 and neoplasm: described “hyperprogressive disease” as a RECIST progression at the first evaluation and a twofold or greater increase in the tumor growth rate (TGR, the percentage increase in tumor volume per month) after starting PD-1/PD-L1 inhibitor therapy compared with the period before initiation of PD-1/PD-L1 inhibitor therapy (150).